JP2023507033A5 - - Google Patents

Info

Publication number
JP2023507033A5
JP2023507033A5 JP2022538373A JP2022538373A JP2023507033A5 JP 2023507033 A5 JP2023507033 A5 JP 2023507033A5 JP 2022538373 A JP2022538373 A JP 2022538373A JP 2022538373 A JP2022538373 A JP 2022538373A JP 2023507033 A5 JP2023507033 A5 JP 2023507033A5
Authority
JP
Japan
Prior art keywords
mutations
domain
polypeptide
protein complex
numbering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538373A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507033A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2020/051753 external-priority patent/WO2021119832A1/en
Publication of JP2023507033A publication Critical patent/JP2023507033A/ja
Publication of JP2023507033A5 publication Critical patent/JP2023507033A5/ja
Pending legal-status Critical Current

Links

JP2022538373A 2019-12-20 2020-12-18 ポリペプチド、タンパク質複合体及びそれを作製する方法 Pending JP2023507033A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951701P 2019-12-20 2019-12-20
US62/951,701 2019-12-20
PCT/CA2020/051753 WO2021119832A1 (en) 2019-12-20 2020-12-18 Polypeptides, protein complexes and method for making same

Publications (2)

Publication Number Publication Date
JP2023507033A JP2023507033A (ja) 2023-02-20
JP2023507033A5 true JP2023507033A5 (cg-RX-API-DMAC7.html) 2023-12-27

Family

ID=76476896

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538373A Pending JP2023507033A (ja) 2019-12-20 2020-12-18 ポリペプチド、タンパク質複合体及びそれを作製する方法

Country Status (8)

Country Link
US (1) US20230242676A1 (cg-RX-API-DMAC7.html)
EP (1) EP4077374A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023507033A (cg-RX-API-DMAC7.html)
CN (1) CN115003693A (cg-RX-API-DMAC7.html)
AR (1) AR120870A1 (cg-RX-API-DMAC7.html)
CA (1) CA3171363A1 (cg-RX-API-DMAC7.html)
TW (1) TWI907375B (cg-RX-API-DMAC7.html)
WO (1) WO2021119832A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240350588A1 (en) * 2021-08-24 2024-10-24 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and use thereof
EP4400512A4 (en) * 2021-09-10 2025-07-23 Soter Biopharma Pte Ltd ANTI-ANG2 ANTIBODY, ITS PREPARATION METHOD AND ITS USE
MX2024003779A (es) 2021-09-29 2024-04-19 Kisoji Biotechnology Inc Agentes de union dirigidos a celulas tumorales que expresan trop2.
WO2023088295A1 (zh) * 2021-11-17 2023-05-25 江苏先声药业有限公司 一种多特异性抗体及其药物用途
EP4599066A1 (en) * 2022-10-03 2025-08-13 Kisoji Biotechnology Inc. Multispecific binding agents targeting dopamine receptor d2 and methods of use thereof
CN120265659A (zh) * 2022-10-25 2025-07-04 加拿大商木曾路生物科技公司 靶向表达cd36的肿瘤细胞的结合剂
KR20250112917A (ko) 2022-12-12 2025-07-24 라노바 메디신즈 리미티드 Pd1 및 vegf를 표적으로 하는 이중특이적 항체
EP4688866A1 (en) * 2023-04-04 2026-02-11 Kisoji Biotechnology Inc. Binding agents targeting trop2-expressing tumor cells
EP4520768A1 (en) * 2023-09-06 2025-03-12 BioNTech SE Vhh-ch3 fusion proteins

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013012733A1 (en) * 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
US9527927B2 (en) * 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
WO2015048272A1 (en) * 2013-09-25 2015-04-02 Amgen Inc. V-c-fc-v-c antibody
CN110981957B (zh) * 2014-01-15 2024-12-24 豪夫迈·罗氏有限公司 具有改善的蛋白A结合作用的Fc区变体
SG10201913507SA (en) * 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
JP6966330B2 (ja) * 2015-05-01 2021-11-17 インヒブルクス,インコーポレイティド Iii型分泌装置標的化分子
WO2016192613A1 (zh) * 2015-06-01 2016-12-08 中山大学 具有融合至常规Fab片段的单域抗原结合片段的二价抗体
JP7328761B2 (ja) * 2016-01-11 2023-08-17 インヒブルクス インコーポレイテッド 多価多重特異性ox40結合融合タンパク質
IL304871A (en) * 2016-01-11 2023-10-01 Inhibrx Inc Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses
DK3529269T3 (da) * 2016-10-19 2026-02-23 Invenra Inc Antistof-konstruktioner
JP7543134B2 (ja) * 2017-10-03 2024-09-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング システイン操作された抗原結合分子
CN111836832A (zh) * 2018-01-08 2020-10-27 南京传奇生物科技有限公司 多特异性抗原结合蛋白及其使用方法
EP3773621A4 (en) * 2018-03-27 2022-03-23 Systimmune, Inc. GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE

Similar Documents

Publication Publication Date Title
JP2025000628A5 (cg-RX-API-DMAC7.html)
JP2021525546A5 (cg-RX-API-DMAC7.html)
JP2021508469A5 (cg-RX-API-DMAC7.html)
JP2019525738A5 (cg-RX-API-DMAC7.html)
JP2021524268A5 (cg-RX-API-DMAC7.html)
JP2021098732A5 (cg-RX-API-DMAC7.html)
JP2020510422A5 (cg-RX-API-DMAC7.html)
JP2021510521A5 (cg-RX-API-DMAC7.html)
JP2023518134A5 (cg-RX-API-DMAC7.html)
RU2021110369A (ru) Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген
JP2023509448A5 (cg-RX-API-DMAC7.html)
JP2023538945A5 (cg-RX-API-DMAC7.html)
US12098203B2 (en) Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
JP2021534762A5 (cg-RX-API-DMAC7.html)
JP2021524267A5 (cg-RX-API-DMAC7.html)
JP2021503455A5 (cg-RX-API-DMAC7.html)
JP2022504802A5 (cg-RX-API-DMAC7.html)
JP2023516004A5 (cg-RX-API-DMAC7.html)
JP2021515798A5 (cg-RX-API-DMAC7.html)
IL276903B1 (en) Bispecific egfr/cd16 antigen-binding protein
JP2018502050A5 (cg-RX-API-DMAC7.html)
JP2018537966A5 (cg-RX-API-DMAC7.html)
JP2025160226A5 (cg-RX-API-DMAC7.html)
JP2014158485A5 (cg-RX-API-DMAC7.html)
JP2021520832A5 (cg-RX-API-DMAC7.html)